Corey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
Corey Fishman
Advertisement
CEO and Founder of Iterum Therapeutics
Articles by Corey Fishman
Iterum Therapeutics receives approval for Orlynvah as the first oral penem for treating uncomplicated urinary tract infections in adult women with limited treatment options.
Advertisement
Latest Updated Articles
SURE1 and REASSURE Trials Paved Way for FDA Approval of OrlynvahPublished: October 30th 2024 | Updated:
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract InfectionsPublished: October 29th 2024 | Updated: October 29th 2024
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Post-Antibiotic Era
3
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
4
